No Data
Another wave! The revised version of the "Biosecurity Act" introduced to the legislative agenda in the US Senate, but the suspense of "breaking through" still lingers.
①On the 23rd local time in the United States, the U.S. Senate will include Amendment S.3558 in the Senate legislative agenda by general order, confirming the new name of the bill, and there is unusual movement in the BrightGene system; ②Amendment S.3558 does not include the "grandfather clause" of the House version of the Biosecurity Act regarding exemptions, nor does it make any changes to the entities involved.
Significant layoffs? Remegen responds: It is a normal business optimization. The recently adapted indication for Taitsip will be applied for listing.
①Regarding the online rumors of layoffs, the secretary of the board of directors of Remegen stated that the company has been sorting out its business since last year, and the optimization of positions and personnel is based on work needs, without a rigid proportion; ②The other party revealed that the severe myasthenia gravis indication of the targeted drug Taituxip is expected to apply for market approval soon. However, Taituxip is facing multiple competitions in the market.
Listed companies have carried out intensive buybacks this week! Wuxi Apptec has launched its third round of 'cancellation-style' buyback plan this year, with a maximum repurchase amount of 0.1 billion yuan. Here is a list of A-share repurchase names.
①This week, the A-share listed companies continue to buy back stocks. According to incomplete statistics from Caixin, 11 listed companies plan to repurchase up to 0.1 billion yuan (see table); ②wuxi apptec, following the completion of the first two repurchase plans on February 5 and May 22, announced another 1 billion yuan repurchase plan on Tuesday evening. After the repurchase is completed, all repurchased shares will be cancelled and the registered capital will be reduced.
Junshi Bio: From a laboratory of less than 300 square meters in 2012 to a leading innovative drug | Zhangjiang's new productive forces
Currently, junshi bio has four innovative drugs, including Teripriline and Adamonab, which have achieved commercial sales. Zhang Zhuobing believes that the research and development of innovative drugs is endless, just like innovation itself. in order for the innovative drug industry to achieve long-term development, it needs to establish an effective system for the transformation of scientific research achievements, which directly affects the industrialization efficiency of biotech enterprises.
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.